Roche cancer drug taking bite out of Bristol's Opdivo
Roche's cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker's treatment is making up lost ground. On Thursday, Bristol-Myers managers said Tecentriq is grabbing market share from its I/O drug Opdivo for second-line non-small-cell lung cancer, one factor that forced them to cut their 2017 earnings forecast. "Most of our erosion in second line has been attributable to" Tecentriq, Murdo Gordon, Bristol-Myers's chief commercial officer, told analysts.
A rush of women going under the knife for designer genitals has taken even plastic surgeons by surprise and divided medical professionals on the ethics and benefits of "labiaplasty". In 2015, more than 95,000 women worldwide underwent the procedure, according to data from the International Society of Aesthetic Plastic Surgery (ISAPS). Most often, labiaplasty involves trimming back the inner "lips" or labia minora flanking the vaginal opening, in a procedure that is also known as nymphoplasty.
No comments:
Post a Comment